Compare SAP SE (SAP) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SAP SE vs Viatris Inc — how do they compare? SAP SE trades at $154.27 (market cap $183.83B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: SAP SE is far larger — about 9.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| SAP | VTRS | |
|---|---|---|
Market Cap | $183.83B | $19.79B |
Sector | Technology | Health |
52-Week High | $307.27 | $17.39 |
52-Week Low | $148.06 | $8.74 |
Enterprise Value | $181.35B | $32.00B |
Dividend Yield | 1.85% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAP trades at $154.34, down 2.96% on the day, amid bearish technical signals despite strong fundamentals. The company reported robust earnings beats in recent quarters with Q1 2026 EPS of $2.01 exceeding expectations of $1.92. Revenue growth remains solid at $36.8B for 2025, with a healthy net income margin of 19.58%. Analyst consensus remains positive with a $222.33 price target, though technical indicators show resistance near $157.
SAP presents a compelling investment case with strong profitability metrics and consistent earnings outperformance. However, near-term technical weakness and competitive pressures in the cloud software space pose risks. The stock's current discount to analyst targets offers potential upside for patient investors focused on the company's AI transformation and cloud growth trajectory.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
